Xinghua Pang

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

Xinghua Pang, Zhaoliang Huang, Tingting Zhong et al. · mAbs · 2023 · 154 citations · Full text

Immunocytochemical Technique, Immunology, Immunodominance +17

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

Tailong Qu, Tingting Zhong, Xinghua Pang et al. · Journal for ImmunoTherapy of Cancer · 2022 · 38 citations · Full text

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Zhaoliang Huang, Xinghua Pang, Tingting Zhong et al. · Frontiers in Immunology · 2022 · 37 citations · Full text

Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects

Tingting Zhong, Lingzhi Zhang, Zhaoliang Huang et al. · iScience · 2024 · 22 citations · Full text

521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies

Tingting Zhong, Zhaoliang Huang, Xinghua Pang et al. · Regular and Young Investigator Award Abstracts · 2022 · 16 citations · Full text

Immunology, Pre-clinical Studies, Immunotherapeutics +18